Brian OConnell

Seeking quantum computing experts for a story on the best quantum stocks in 2026 Hola, Folks . . . We're writing up a story on the best quantum computing stocks and ETFs to buy these days for US News and need these queries answered for the story. 1. What do you make of the quantum computing market right now? Is QC still well-finded and on track for commercial application timelines? 2. Is the QC market vulnerable too the tariff wars right now, especially industry companies tied to the Chinese economy? 3. Which QC stocks do you like right now and why? 4. which quantum ETFs do you like right now and why? 4. Any advice for newbie investors looking to get into QC stocks/funds?

Hola Folks, we're working on a story on The White House saying $500 refunds will go to nearly 1 million ACA enrollees in 30 states who do not receive premium assistance, with checks beginning in October. The administration says the money represents excess federal-exchange user fees, while questions remain about the calculation, funding mechanism and legal authority for the payments. We'd like to get some expert opinions on the payments and the policy, and need these queries answered for the story. 1. Who exactly qualifies for the $500 ACA refund, and is there evidence that these individuals were actually overcharged by roughly $500? How should consumers determine whether they are eligible, and what should they do if they believe they qualify but don't receive a check? 2. The administration says the refunds come from excess ACA exchange user fees. How does that funding mechanism work, and does the administration have the legal authority to distribute this money directly without additional congressional approval? What unanswered questions remain about where the money is coming from? 3. How meaningful is a one-time $500 payment compared with what ACA consumers are currently paying for health insurance? For a middle-income household buying unsubsidized coverage, how much of its annual premium or recent premium increase would $500 realistically offset? 4. Critics argue that the rebate should be viewed alongside the expiration of enhanced ACA premium tax credits, while the administration describes it as returning excess fees to consumers. What is the fairest apples-to-apples comparison? Who financially gained or lost from the recent ACA policy changes, and by approximately how much? What are the longer-term implications of returning ACA exchange surpluses directly to consumers rather than using those funds to reduce premiums or improve the marketplace? Could this become a sustainable health-care policy tool, or does it do little to address the underlying forces driving insurance and medical costs?